Life Sciences Tools and Instruments M&A update, 14–28 September 2026
This bi-weekly update tracks public market moves, major news and M&A activity across Life Sciences Tools and Instruments for September 14–28, 2026, giving operators, acquirers and advisors a concise read on what changed, who moved, and what it means for pricing and strategy.
For information only. Not an appraisal or a fairness opinion.
The deeper read: Life Sciences Tools and Instruments Sector Outlook — September 2026
Key figures
- Median covered-set move
- +18.2%
- 12 names, close-to-close
- S&P 500 return
- +0.8%
- same two-week period
- Pacific Biosciences (PACB) return
- +26.7%
- two-week period
- Precedent transactions multiple
- 19.5x
- EV/LTM EBITDA, 40 deals
Read the report
1 / 7 · HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › LIFE SCIENCES TOOLS AND INSTRUMENTS
Executive summary
Across September 14–28, 2026, the covered set of 12 life sciences tools and instruments companies rose broadly, with a median move of +18.2% against the S&P 500's +0.8%. Pacific Biosciences (PACB) led the group at +26.7%, while Revvity, Agilent and Cytek Biosciences advanced assay menus into clinical and regulated workflows. No new transactions were announced in the period, leaving the trailing record of 40 precedent transactions at a median 19.5x EV/EBITDA as the reference for pricing.
Key findings
- 11 of 12 covered names rose; median move +18.2% vs S&P 500 +0.8%.
- Pacific Biosciences (PACB) led the group, up +26.7% over the two-week period.
- Companies expanded assay menus into clinical use rather than signing new deals.
- No new transactions; 40-deal trailing record at 19.5x EV/EBITDA still frames pricing.
What each page shows
The analyst’s walkthrough of the deck, page by page.
- 01BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE
HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › LIFE SCIENCES TOOLS AND INSTRUMENTS
Cover page introducing the bi-weekly Life Sciences Tools and Instruments industry events and M&A update for September 14–28, 2026.
We open this bi-weekly update on Life Sciences Tools and Instruments, covering what changed, who moved, what transacted, and what it means for the two weeks ended September 28, 2026. This sets the frame for the sector read that follows.
Everything on this page
BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › LIFE SCIENCES TOOLS AND INSTRUMENTS Clinical Migration Pulls the Sector Higher as New Launches Land What moved, what companies did, and what changed in the transaction record across Life Sciences Tools and Instruments from September 14–28, 2026. September 14–28, 2026 Prepared by NeuraCap AI · Confidential Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28 Life Sciences Tools and Instruments Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 1
- 02THE BI-WEEKLY BOTTOM LINE
Launches Aimed at Regulated Workflows, Not New Transactions, Carried the Period
Summarizes the two-week period: 11 of 12 covered names rose, with a median move of +18.2%, while no new transactions were signed.
We start with the headline: 11 of 12 covered names rose over the two-week period, and the median move of +18.2% ran well ahead of the S&P 500's +0.8%. The push came from companies extending their assay menus into clinical and regulated workflows rather than from new deal activity. Pacific Biosciences led the group, and Bio-Techne shareholders approved their already-agreed merger. So what: this period rewarded operational moves into clinical positioning more than transaction news.
Everything on this page
THE BI-WEEKLY BOTTOM LINE Launches Aimed at Regulated Workflows, Not New Transactions, Carried the Period The two-week period in one page · 12 covered names, close-to-close · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Driver attributions use calibrated language and are NeuraCap reads of the recorded evidence. Life Sciences Tools and Instruments Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 2 1 11 of 12 Covered Names Rose; The Median Move Was +18.2% The covered set ran well ahead of the S&P 500, which returned +0.8% over the same two-week period. Only one covered name finished lower. 2 Pacific Biosciences Led the Covered Set PACB returned +26.7% over the two-week period, with its largest single day, +12.1%, on Sep 24. Zacks reported closes of $1.38 on Sep 17 and $1.62 on Sep 25. 3 Companies Spent the Period Extending the Assay Menu into Clinical Use Revvity, Inc. (RVTY) launched a CE-IVDR-certified multiplex screening kit, Agilent Technologies, Inc. (A) launched TapeStationDx for clinical NGS sample quality control, and Cytek Biosciences, Inc. (CTKB) extended its cloud analysis tools. The NeuraCap read: the work this period went into menu and workflow ownership rather than placements alone. 4 No New Transactions Signed; The Trailing Record Remains the Reference No material sector transactions were announced during the period. The trailing record of 40 precedent transactions carries a median of 19.5x EV / EBITDA, and Bio-Techne Corporation (TECH) shareholders approved their already-agreed merger on Sep 23. +26.7% Best mover — PACB worst: MXCT -1.7% · 11 up / 1 down of 12 covered +18.2% Sector median two-week return vs S&P 500 +0.8%
- 03PUBLIC MARKET MOVERS
A Core-Tier Sequencing Platform Set the Pace While One Discount-Tier Name Sat Out
Shows individual public market moves for covered names over the two-week period, led by a core-tier sequencing platform.
We highlight the public market movers for the two-week period, where a core-tier sequencing platform set the pace and one discount-tier name sat out the rally. The median move across the covered set was +18.2%, against a materiality bar of ±27.3% on a sector-relative basis. Pacific Biosciences led the group at +26.7%, with its largest single day at +12.1%. So what: the dispersion tells us which names the market is rewarding for clinical positioning versus which are being left behind.
Everything on this page
PUBLIC MARKET MOVERS A Core-Tier Sequencing Platform Set the Pace While One Discount-Tier Name Sat Out Bi-Weekly moves, close-to-close · September 14–28, 2026 · sector median +18.2% · S&P 500 +0.8% · materiality bar ±27.3% (sector-relative) Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Attribution links each move only to filings and headlines recorded in the window; where no driver is recorded, the page says so. Calibrated language throughout — NeuraCap reads, not asserted causation. Life Sciences Tools and Instruments Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 3 Bi-Weekly return per company · teal above zero, amber below · sector median +18.2% Pacific Biosciences of California, Inc. (PACB) +26.7% Shares of Pacific Biosciences of California, Inc. (PACB) moved following the Sep 20 report that the company is sharpening execution around clinical genomics, cost controls and $40M of savings behind its HiFi sequencing push. A Core-tier platform can re-rate on clinical positioning and cost discipline before placements show it. COMPANY-SPECIFIC MaxCyte, Inc. (MXCT) -1.7% No notable in-window news was identified that clearly explains the move. MaxCyte, Inc. (MXCT) returned -1.7% against a covered-set median of +18.2%. A Discount-tier name can stand apart from a broad advance across the covered set. UNEXPLAINED
- 04MAJOR NEWS & INDUSTRY CATALYSTS
What Companies Actually Did: Menu Expansion, Workflow Ownership and One Shareholder Vote
Details the period's highest-impact company actions: menu expansion, workflow ownership moves and one shareholder vote.
We walk through what companies actually did this period: Revvity launched a CE-IVDR-certified multiplex screening kit, Agilent launched TapeStationDx for clinical NGS sample quality control, and Cytek Biosciences extended its cloud analysis tools. Bio-Techne shareholders also approved their already-agreed merger on Sep 23. So what: the events show the sector is investing in regulated-workflow ownership, a signal for where competitive advantage is being built.
Everything on this page
MAJOR NEWS & INDUSTRY CATALYSTS What Companies Actually Did: Menu Expansion, Workflow Ownership and One Shareholder Vote The two-week period's highest-impact events · titles link to the underlying filing or article · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. "Why it matters" lines are NeuraCap reads; each event links to its source. Sources are admitted in a fixed reliability order (SEC filings, press releases, established outlets); video and social platforms are never used. Life Sciences Tools and Instruments Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 4 Sep 24 · NEWS · Business Wire Revvity launches a CE-IVDR-certified multiplex kit for early detection of type 1 diabetes A fully automated, IVDR-certified kit aimed at population-wide screening moves a Premium-tier assay menu from research use into a regulated clinical setting. Regulated menu expansion raises pull-through on an existing installed base. Sep 23 · NEWS · GlobeNewsWire MaxCyte appoints Sidharth Kapileshwar as Chief Corporate Development Officer Adding a dedicated corporate development seat signals a cell engineering platform building capacity to pursue partnerships and portfolio moves from a Discount-tier starting point. Platform companies often build corporate development capability before the record shows activity. Sep 23 · NEWS · PRNewsWire Bio-Techne shareholders vote to approve and adopt the definitive merger agreement A Premium-tier reagents and diagnostics franchise cleared its shareholder vote on an already-agreed transaction. The NeuraCap read: scaled strategic appetite for proprietary consumables streams remains live. Proprietary chemistry and reagent IP remain the assets buyers pursue in this sector. Sep 23 · NEWS · GlobeNewsWire Cytek adds a Cloud Analysis tool, extending its Cytek Cloud digital ecosystem Adding analysis to instruments and reagents moves the company closer to owning the full sample-to-answer path in flow cytometry rather than supplying one step inside someone else's workflow. Software attached to the installed base defends workflow ownership without new placements. Sep 22 · NEWS · PRNewsWire Bio-Techne opens a Düsseldorf customer experience centre serving DACH and EMEA Hands-on access to technologies and workflows is how validated methods spread and switching costs build. It also thickens the service and training footprint behind the aftermarket annuity. Service network density is a value driver, not an overhead line. Sep 22 · NEWS · PRNewsWire Danaher schedules its third-quarter 2026 earnings call for October 21 A calendar item rather than new information. It sets the date on which a Core-tier diversified platform gives the sector its next read on instrument demand and book-to-bill. The next demand signal for the group is dated, not delivered.
- 05M&A & STRATEGIC ACTIVITY
Operators Built; The Transaction Record Stood Still
Reviews the trailing M&A record of 40 precedent transactions at a median 19.5x EV/LTM EBITDA, noting no new transactions signed in the period.
We turn to the transaction record, where no new sector transactions were announced this period. The trailing record stands at 40 precedent transactions, with a median multiple of 19.5x EV/LTM EBITDA, and that remains the reference point for how deals are being priced. So what: with the record unchanged, acquirers and targets alike are still anchored to this trailing multiple until a new transaction resets it.
Everything on this page
M&A & STRATEGIC ACTIVITY Operators Built; The Transaction Record Stood Still September 14–28, 2026 · precedent transactions: 40 recorded deals · median 19.5x EV/LTM EBITDA Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Deal multiples are LTM at announcement where disclosed; "why the deal happened" is a NeuraCap read of the recorded evidence. No old transactions are re-presented as news. Life Sciences Tools and Instruments Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 5 No Material Transactions Announced No material sector transactions were announced during the period. The only transaction-related development was the Bio-Techne Corporation (TECH) shareholder approval of an already-agreed merger, leaving the trailing record of 40 precedent transactions, at a median of 19.5x EV / EBITDA A quiet two-week period is information: buyer appetite, financing conditions and seller expectations all read through a period with no new deals. The precedent transactions alongside still frame what buyers have paid. 40 Recorded precedent transactions the reference set buyers and sellers price against 19.5x Precedent median EV/LTM EBITDA LTM at announcement, where disclosed
- 06WHAT IT MEANS
What the Two-Week Period Changes for Operators, Buyers and Advisors
Translates the period's developments into implications for operators, acquirers and advisors.
We close with what this two-week period means for the people who act on it. For owners and operators, menu and mix did the work, as companies rose while news flow centered on assay menu and clinical positioning. For acquirers, the reference set is unchanged at 40 precedent transactions and 19.5x EV/EBITDA, even as the asset-quality conversation shifts toward regulated workflows. So what: advisors should lead with the research-to-regulated migration story, since the covered set's median move of +18.2% shows the market is already following it.
Everything on this page
WHAT IT MEANS What the Two-Week Period Changes for Operators, Buyers and Advisors The two-week period translated for the people who act on it · NeuraCap view · observations, not recommendations Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. This page is analytical interpretation drawn from the two-week period's recorded evidence. It is not investment advice. Life Sciences Tools and Instruments Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 6 Sector study 2026-09-28 EV / Revenue (CY2027E) median 5.2x 12 companies in the study 3 valuation tiers Standing thesis: Life Sciences Tools prices cell and gene therapy platforms differently from laboratory monitoring instruments FOR OWNERS & OPERATORS Menu and Mix Did the Work This Period Companies in the space traded higher while the news flow was about assay menu, clinical positioning and workflow ownership. FOR ACQUIRERS The Reference Set Is Unchanged; The Asset Quality Question Moved No new transactions were signed, so the trailing record of 40 precedent transactions at a median of 19.5x EV / EBITDA still frames pricing. FOR ADVISORS Lead with the Research-to-Regulated Story The dominant theme was migration from research-use-only into clinical and screening workflows, and the covered set rose with it: 11 of 12 covered names rose; the median move was +18.2%.
- 07SOURCES & METHODOLOGY
Sources, Methodology and Important Notice
Explains the sources and methodology behind the update, including how figures are sourced and verified.
We close with the sources and methodology behind this update, so every figure can be traced back to its underlying record. Market data runs through September 28, 2026, and driver attributions use calibrated language reflecting our read of the recorded evidence. So what: this gives readers confidence that every claim in the deck is traceable and appropriately hedged.
Everything on this page
SOURCES & METHODOLOGY Sources, Methodology and Important Notice How this bi-weekly update is built and what each kind of statement rests on · September 14–28, 2026 · market data through 2026-09-28 Every figure in this update links to the record it was taken from; the publishers and filings drawn on for the period are listed above. Life Sciences Tools and Instruments Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice 7 OBSERVED DATA Bi-Weekly stock moves are computed close-to-close over the stated window from the platform’s price series. Deal records, values and multiples come from the platform’s transaction record (SEC 8-K extractions) exactly as recorded; each figure links to its citation. Treasury rates come from the platform’s Treasury series and are shown only when the 10-year moved at least ten basis points over the window (it did not in this window, so no rate figures appear). UNIVERSE QUALITY The update universe is the platform’s approved company set for this sector, subject to a $100M market-cap floor so small, loosely related names cannot dominate the statistics. No covered name fell below the floor in this window. EVENTS & NEWS Company events are in-window 8-K filings; news items are publisher-sourced headlines fetched for the window (and any externally supplied items, marked as such). Operational and strategic developments (deals, partnerships, launches, expansion, guidance, leadership, regulatory outcomes) are shown first; capital-return mechanics and conference appearances are limited to one each. Every event links to its source. The deck never asserts an event that has no linked record. SOURCE HIERARCHY News is admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then transaction documents, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron’s and peers). Video and social platforms — including YouTube — are never used as sources. DRIVER ATTRIBUTION A stock move is linked to an event only when the event falls inside the window, and only in calibrated language ("the move appears to reflect…", "shares moved following…"). Where no driver is recorded, the page says so and compares the move to the sector median instead. ANALYTICAL INTERPRETATION "Why it matters", "why the deal happened" and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, and are labeled as such. INHERITED CONTEXT The standing sector view (thesis, valuation lens, sector median and tiering) is inherited from the NeuraCap sector study run_20260929T212308Z_570_prod (market data as of 2026-09-28) — distilled, never re-derived. That report’s own sources page governs its content; this update reads the period against it. IMPORTANT NOTICE This report is informational only. It is not investment advice, not a recommendation to buy or sell any security, and not an offer of any kind. Readers should perform their own diligence before acting on anything described here. Linked sources this two-week period: businesswire.com · globenewswire.com · prnewswire.com
Sources and methodology
This update covers Life Sciences Tools and Instruments over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 12 listed companies whose core business is Life Sciences Tools and Instruments under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: Agilent Technologies, Inc. (A), Bruker Corporation (BRKR), Cytek Biosciences, Inc. (CTKB), Danaher Corporation (DHR), Standard BioTools Inc. (LAB), 908 Devices Inc. (MASS), Mesa Laboratories, Inc. (MLAB), MaxCyte, Inc. (MXCT), Pacific Biosciences of California, Inc. (PACB), Revvity, Inc. (RVTY), Bio-Techne Corporation (TECH), 10x Genomics, Inc. (TXG). No covered name fell below the floor in this window.
Window and company universe
This update covers Life Sciences Tools and Instruments over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 12 listed companies whose core business is Life Sciences Tools and Instruments under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: Agilent Technologies, Inc. (A), Bruker Corporation (BRKR), Cytek Biosciences, Inc. (CTKB), Danaher Corporation (DHR), Standard BioTools Inc. (LAB), 908 Devices Inc. (MASS), Mesa Laboratories, Inc. (MLAB), MaxCyte, Inc. (MXCT), Pacific Biosciences of California, Inc. (PACB), Revvity, Inc. (RVTY), Bio-Techne Corporation (TECH), 10x Genomics, Inc. (TXG). No covered name fell below the floor in this window.
How the moves and statistics are computed
Each company's period move is the change in closing price from the last close before the window to the last close inside it (close-to-close). The sector median is the median of those moves across the covered names; the index return is computed the same way for the S&P 500 over the same dates. The largest single-day move inside the window is shown for each mover. Movers are the largest gainers and losers by period move; the attribution cards prefer movers whose in-window record explains the move. Movers carry the valuation tier assigned in the standing sector study (the latest NeuraCap sector outlook) where that study rated them.
Events, news and how a move is attributed
Company events are the 8-K filings made inside the window; news items are publisher-sourced headlines for the window, admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron's and peers). Video and social platforms are never used. A move is linked to an event only when the event falls inside the window and only in calibrated language; where nothing in the record explains a move, the update says so rather than speculating. Every event links to its source.
Transactions in the window and the trailing record
Transactions are taken from SEC filings by announcement date; 0 were announced inside the window. The trailing record of 40 recorded transactions provides the reference multiples (EV over last-twelve-month revenue or EBITDA at announcement, as disclosed). A value whose own citation describes something other than the price paid is not shown as the deal value; transactions where the acquirer and the target are the same entity are treated as reorganisations and excluded.
Sources
Prices and index levels are market data through September 28, 2026; filings are the companies' SEC filings on EDGAR; press releases are the companies' own; other news items are from the established outlets named on each card; Treasury yields are published by the U.S. Department of the Treasury. Every figure and every event in the update links to its record.
Interpretation and important notice
'Why it matters', 'why the deal happened' and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, labelled as such. The update is informational: it is not investment advice, not a recommendation to buy or sell any security and not an offer of any kind.
Sources linked in the report
- +26.7% (seekingalpha.com)
- -1.7% (globenewswire.com)
- Revvity launches a CE-IVDR-certified multiplex kit for early detection of (businesswire.com)
- Bio-Techne shareholders vote to approve and adopt the definitive merger (prnewswire.com)
- Cytek adds a Cloud Analysis tool, extending its Cytek Cloud digital (globenewswire.com)
- Bio-Techne opens a Düsseldorf customer experience centre serving DACH and (prnewswire.com)
- Danaher schedules its third-quarter 2026 earnings call for October 21 (prnewswire.com)
- businesswire.com (businesswire.com)
This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.
More coverage in Health Care
- Sector Outlook · 29 September 2026Life Sciences Tools and Instruments Sector Outlook — September 2026
- M&A Update · 29 September 2026Managed Health Care M&A update, 14–28 September 2026
- Sector Outlook · 29 September 2026Managed Health Care Sector Outlook — September 2026
- M&A Update · 29 September 2026Medical Devices M&A update, 14–28 September 2026
Want this analysis for a company in Life Sciences Tools and Instruments?
Company valuation reports run the same method against a single business — public or private.
